Skip to main content

Table 2 Baseline characteristics, metabolic changes and patients’ self-evaluation of metreleptin therapy according to the type of lipodystrophy

From: Adherence with metreleptin therapy and health self-perception in patients with lipodystrophic syndromes

   Partial LD (n = 10) Generalized LD (n = 10) p
Baseline characteristics Age (years) 43.0 (33.2;50.0) 16.5 (11.7;34.7) 0.04
BMI (kg/m2) 25.0 (22.9;26.5) 20.9 (19.6;24.1) 0.035
Leptinemia (ng/mL) 4.0 (2.9;4.8) 1.0 (0.1;2.3) 0.003
HbA1c (%) 7.8 (7.1;10.6) 8.5 (7.1;10.8) 0.73
Tg (mmol/L) 3.1 (1.9;14.1) 5.1 (2.7;11.0) 0.97
Metabolic changes Delta HbA1c (%) −0.7 (− 0.2; − 1.2) −1.2 (− 0.1; −2.9) 0.6
Delta Tg (mmol/L) − 0.2 (−4.6;0.8) − 1.7 (− 0.1;-7.9) 0.2
Delta BMI (kg/m2) −1.9 (− 1.3;-2.7) − 0.8 (− 1.4; 0.2) 0.035
Delta number of anti-diabetic medications 0 (− 1;1) 0 (− 3; 1) 0.94
Delta number of patients under insulin −1 − 3  
Self-evaluation of treatment Efficiency 66.7 (58.3;83.3) 70.8 (47.9;77.1) 0.59
Side effects 100 (91.7;100) 95.8 (50;100) 0.32
Ease and comfort of use 61.1 (50;66.7) 50.0 (41.7;59.7) 0.30
Global satisfaction 83.3 (64.6;83.3) 70.8 (50.0;83.3) 0.36
Changes in physical appearance 6 ++ 2 + 1 NC 1 - 4 ++ 1 + 2 - 1 - - 2 NC  
Changes in social interactions 4 ++ 6 + 5 ++ 2 + 1 - - 2 no effect  
Adherence Acceptable or excellent metreleptin adherence (number of patients) 9 6  
  1. Tg triglycerides, LD lipodystrophy
  2. Patients with acceptable or excellent metreleptin therapy adherence were classified as “compliant” whereas patients with poor metreleptin therapy adherence were considered as “non compliant”; Self-evaluation of the effect of metreleptin therapy was ++ significantly improved, +improved, 0 neutral, − worsened, or -- significantly worsened; NC not concerned